Triple-negative breast cancer is aggressive and hard to treat because it resists so much. Researchers have found a way to corner it: a one-two punch that forces the cells to destroy themselves.
Scientists at the Medical University of South Carolina Hollings Cancer Center, led by Dr Ozgur Sahin, reported in Cell Reports Medicine that blocking LOX (lysyl oxidase) weakens TNBC cells and pushes them onto a backup survival pathway controlled by DHODH — and blocking that too triggers ferroptosis.
Why triple-negative breast cancer is different
Most breast cancers are defined by what they express: oestrogen receptor, progesterone receptor, or HER2. Each provides a target, and drugs against each have transformed outcomes.
Triple-negative tumours express none of the three. The name describes an absence, and that absence is the clinical problem — hormone therapy and HER2-directed drugs are useless, leaving chemotherapy as the backbone. TNBC also tends to affect younger women, to be more aggressive, and to recur earlier.
What ferroptosis is
Ferroptosis is a distinct form of cell death, discovered comparatively recently, and it is not the apoptosis most cancer drugs try to induce.
It is iron-dependent and driven by lipid peroxidation — oxidative damage to the fats making up cell membranes. Once it passes a threshold, membranes lose integrity and the cell dies.
Its appeal in oncology is precisely that it is a different route. Cancer cells commonly acquire resistance to apoptosis by disabling the machinery that executes it, which is why so many treatments eventually stop working. Ferroptosis uses different machinery, so a cell that has become expert at avoiding apoptosis has no particular defence against it.
The trap being set
The strategy is more interesting than simply combining two drugs.
Blocking LOX weakens TNBC cells and pushes them toward ferroptosis — but they survive by shifting onto a backup antioxidant pathway controlled by DHODH, which neutralises the lipid damage before it reaches lethal levels. On its own, LOX inhibition provokes an escape rather than a kill.
The insight is to let that escape happen and then close it. “First, we block LOX, which weakens the cancer cells…we deliver the second punch by blocking that pathway, too,” Sahin said.
What makes this elegant is that the second drug targets the cell’s own resistance mechanism. Rather than fighting resistance, the approach makes resistance the vulnerability — the cells are killed by the very adaptation that was supposed to save them.
Half the combination already exists
The team paired an experimental LOX inhibitor with leflunomide, an already FDA-approved drug that blocks DHODH.
That matters considerably for translation. Leflunomide has been used for years in rheumatoid arthritis, so its safety profile, dosing and pharmacokinetics in humans are established. Only one novel agent needs to clear the full development path, which removes a substantial share of the usual risk and time from a combination programme.
What the experiments showed
Across multiple patient-derived tumour models — including chemotherapy-resistant ones — the combination significantly blocked tumour growth, and it outperformed the LOX inhibitor plus standard chemotherapy, without major weight loss or kidney and liver toxicity.
Two details raise confidence. Patient-derived models retain more of the heterogeneity of real tumours than long-established cell lines, which behave in ways that flatter drug candidates. And beating LOX inhibition plus chemotherapy is a more demanding comparison than beating no treatment.
The chemotherapy-resistant models are the most relevant, because those patients are the ones with the fewest options.
The caveats
This is preclinical work in laboratory and patient-derived models. The researchers hope to complete human safety testing within a few years, which is a realistic timeline and also a distant one.
Ferroptosis-based strategies carry a general concern worth noting: the pathway operates in normal cells too, and some healthy tissues are sensitive to lipid peroxidation. The absence of major toxicity in animal models is encouraging but does not guarantee a workable therapeutic window in people.
Combination toxicity is also unpredictable. Two drugs individually tolerable can be problematic together, and leflunomide has its own liver-related cautions in rheumatology use.
Why the approach generalises
The most transferable element is not the specific drugs but the logic: identify what a cancer cell does to survive an attack, then block that escape route rather than attacking harder.
Why LOX was a target in the first place
Lysyl oxidase is not an obvious cancer target, and the reason it attracted attention says something about how tumours behave.
LOX cross-links collagen and other structural proteins in the tissue surrounding cells, and in cancer it contributes to stiffening the tumour environment. That stiffening is not incidental: it supports invasion, influences how cells migrate, and has been associated with the preparation of distant tissue sites before metastatic cells arrive. LOX has therefore been of interest primarily as a target in metastasis rather than in the primary tumour.
What this work adds is an unexpected second role. Blocking LOX turns out to leave the cancer cell metabolically vulnerable in a way that has nothing to do with tissue architecture — pushing it toward oxidative membrane damage and forcing the antioxidant compensation the second drug exploits. Discovering that an enzyme studied for its structural function also gates a cell’s oxidative defences is the kind of finding that produces combinations nobody would have designed from first principles.
Resistance is usually treated as the thing that defeats therapy. Designing around it deliberately — provoking an adaptation and then removing it — is a strategy applicable well beyond this pairing, and it is a compelling one for a subtype with so few targeted options. Preclinical research; not medical advice.